Halozyme Therapeutics has retired 21.7% of its shares since 2018, from 145,033,173 to 113,498,000.
At $121.84 a share, a market value of $13.8B. FCF yield 5.8%, P/E 33.4, trailing twelve months to June 2026.
| Fiscal year | Date | Shares outstanding | Filing | |
|---|---|---|---|---|
| 2006 | 2007-02-28 | 71,042,402 | 10-K | cover page |
| 2007 | 2008-03-01 | 78,432,949 | 10-K | cover page |
| 2008 | 2009-02-27 | 82,946,449 | 10-K | cover page |
| 2009 | 2010-03-01 | 91,712,381 | 10-K | cover page |
| 2010 | 2010-12-31 | 100,580,849 | 10-K | |
| 2011 | 2012-03-01 | 112,093,601 | 10-K | |
| 2012 | 2013-02-25 | 113,122,900 | 10-K | |
| 2013 | 2014-02-24 | 124,003,650 | 10-K | |
| 2014 | 2015-02-24 | 126,704,135 | 10-K | |
| 2015 | 2016-02-22 | 129,061,401 | 10-K | |
| 2016 | 2017-02-22 | 129,764,415 | 10-K | |
| 2017 | 2018-02-13 | 143,076,590 | 10-K | |
| 2018 | 2019-02-14 | 145,033,173 | 10-K | |
| 2019 | 2020-02-14 | 138,226,070 | 10-K | |
| 2020 | 2021-02-17 | 135,276,380 | 10-K | |
| 2021 | 2022-02-14 | 137,703,510 | 10-K | |
| 2022 | 2023-02-14 | 135,366,862 | 10-K | |
| 2023 | 2024-02-12 | 126,824,800 | 10-K | |
| 2024 | 2025-02-11 | 123,153,000 | 10-K | |
| 2025 | 2026-02-10 | 118,017,000 | 10-K |
Source: all 10-K filings of Halozyme Therapeutics on EDGAR. Download this series as CSV. Licence CC BY 4.0, credit Buyback Radar.
The story
Every Monday we write about one of these companies.
Read the full storyCash spent comes from the cash flow statement. Shares outstanding fell by less than the company bought, because part of every buyback only replaces shares handed to employees. Today’s price is $121.84.
Loading the chart from TradingView…
All-time chart by TradingView. Open it on TradingView →
Yes. Halozyme Therapeutics has 3.5% fewer shares outstanding than twelve months ago, 113,498,000 as of July 31, 2026. Over five years the share count is down 19.4%.
Net of every new share it issued, Halozyme Therapeutics has 31.5 million fewer shares than at its 2018 peak. That is 21.7% of the company. Since fiscal 2019 alone it bought back about 30.2 million shares, while the count fell by 24.7 million. The difference went to employees and other new shares.
113,498,000 shares, as of July 31, 2026, from the cover page of its latest 10-Q. At the 2018 peak it had 145,033,173.
Each share is a bigger slice of the company. Someone who held Halozyme Therapeutics stock in 2018 owns 1.3 times as much of the business today without buying another share. Whether that was a good use of cash depends on the price paid.
Halozyme Therapeutics ranks No. 352 of 467 companies on Buyback Radar by share of the company retired since its peak. Close to it on the list: Acushnet (22.2%), Genuine Parts (22.0%), Trimas (21.5%), Old Republic International (21.5%).
Every answer is computed from Halozyme Therapeutics' own SEC filings and rebuilt every Monday. Latest count: 10-Q on EDGAR.
From the latest 13F filings. All superinvestors.
Free. Your email goes to Substack, which runs the newsletter. Privacy